{"id":677666,"date":"2023-11-21T17:40:01","date_gmt":"2023-11-21T17:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=677666"},"modified":"2023-11-21T17:40:01","modified_gmt":"2023-11-21T17:40:01","slug":"elitone-urge-is-empowering-an-aging-population-to-outsmart-big-pharma-unveiled-at-ces-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/elitone-urge-is-empowering-an-aging-population-to-outsmart-big-pharma-unveiled-at-ces-2024_677666.html","title":{"rendered":"“Elitone Urge” is Empowering An Aging Population to Outsmart Big Pharma: Unveiled at CES 2024"},"content":{"rendered":"
\""Elitone<\/a><\/div>\n
Elitone Urge was selected as an Innovation Award honoree at CES in the Accessibility & Aging Tech category.<\/div>\n

Las Vegas, NV – November 21, 2023 –<\/strong> ELITONE® URGE<\/a>, the only FDA-cleared OTC solution for Overactive Bladder (OAB), has been honored with the prestigious Innovation Award at CES 2024 in the Accessibility and Aging Tech category. This recognition marks a pivotal moment for ELITONE, as they redefine the landscape of urinary incontinence treatment for women, and empower older adults to live longer, healthier, more enjoyable lives. <\/p>\n

Aging tech is a necessity in a population where in just ten years, there will be more people over 65 than under 18<\/a>.  1 in 2 women <\/a>over the age of 50 experience incontinence. The only current solutions to pelvic floor and bladder health are painful, ineffective, and even dangerous with 50% of women on incontinence medication <\/a>experiencing dementia within 6 months. <\/p>\n

In an industry dominated by dangerous medications and invasive surgeries , ELITONE URGE’s innovative approach stands as a beacon of hope for millions of Americans grappling with the challenges of urinary incontinence. Unlike conventional treatments, ELITONE URGE offers an effective, FDA-cleared, and non-invasive alternative that enables women to reclaim control over their lives.<\/p>\n

94% of women improve their incontinence with the use of ELITONE URGE with no side effects.  In just six weeks, clinical studies have shown 85% achieved a clinically significant reduction in leaks (ELITONE<\/a>.) ELITONE URGE requires no surgery, no medications, no prescription, is doctor-recommended, and clinically tested. <\/p>\n

ELITONE URGE’s discreet and user-friendly design allows women to integrate the treatment seamlessly into their daily routines without disruptions or uncomfortable side effects.  Worn for just 20-minutes a day and external, ELITONE URGE precisely delivers pelvic floor stimulation to effectively treat incontinence  Backed by a legacy of nine patents and rigorous research and clinical trials, ELITONE URGE makes it possible for women to ditch the pads, treat leaks, and embrace life. <\/p>\n

Gloria Kolb, the tenacious CEO and Co-Founder of ELITONE envisions the CES 2024 recognition as more than just an award; it’s a testament to the tireless dedication of a team committed to challenging the status quo.<\/p>\n

“We’ve always believed in providing a better, safer alternative for women dealing with bladder leaks. Medications have a lot of bad side effects and are not well-tolerated. ELITONE URGE offers the only at-home solution for urge incontinence. The fact that it is easily wearable and doesn’t take up your time, while stimulating the nerves and tissue makes it truly revolutionary,” said Gloria Kolb, CEO and co-founder of ELITONE. “Together, we’re challenging the norms and standing firm in our commitment to empowering women,” she adds.<\/p>\n

Gloria Kolb was inspired to create ELITONE following the birth of her twins. Her journey with urinary incontinence led her to recognize the need for a more convenient and non-intrusive solution for women experiencing similar challenges. Gloria, along with co-founder Eric Kolb, harnessed their professional experience in designing medical devices to develop a better solution. After eight years of dedicated research and development, ELITONE and ELITONE URGE are available to help women regain control and regain confidence®.<\/p>\n

As ELITONE URGE prepares to unveil its story at CES 2024, the team invites attendees to witness the future of OAB treatment and join the movement toward a safer, more effective approach to urinary incontinence.<\/p>\n

For more information about ELITONE URGE and its mission to redefine the standards of OAB treatment, please visit ELITONE.com.<\/p>\n

Gloria Kolb, CEO and co-founder of ELITONE<\/strong><\/p>\n

Gloria Kolb is the CEO and co-founder of Elidah, maker of ELITONE®, an FDA-cleared, non-invasive wearable treatment for women with urinary incontinence.<\/p>\n

As an inventor with 30 patents, Gloria’s accolades include Best New Product of 2019 by My Face My Body awards, Sling Shot 2020, and a top 10 finalist in Google’s Women Startup Challenge. Gloria has also been featured in Forbes as a Top Scientist Driving Innovation in Women’s Health. Her creative designs and problem-solving abilities have earned her recognition, such as Boston’s “40 Under 40” Award and MIT Review’s “World’s Top Innovators under 35”.<\/p>\n

She has Engineering degrees from MIT and Stanford and an Entrepreneurship MBA from Babson College. Elidah is a participant of the AgeTech Collaborative™ from AARP® Accelerator program.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Otter PR<\/a>
Contact Person:<\/strong> Kelly Johnson
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 8136786828
Address:<\/strong>100 E Pine St Suite 110
City:<\/strong> Orlando
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> OtterPR.com<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Elitone Urge was selected as an Innovation Award honoree at CES in the Accessibility & Aging Tech category. Las Vegas, NV – November 21, 2023 – ELITONE® URGE, the only FDA-cleared OTC solution for Overactive Bladder (OAB), has been honored … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[424,405,437,422,411],"tags":[],"class_list":["post-677666","post","type-post","status-publish","format-standard","hentry","category-Family-Parenting","category-Health-Medicine","category-Lifestyle","category-Retail","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/677666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=677666"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/677666\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=677666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=677666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=677666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}